Stay updated on Ipilimumab Nivolumab Radiation in HPV+ Oropharyngeal Clinical Trial

Sign up to get notified when there's something new on the Ipilimumab Nivolumab Radiation in HPV+ Oropharyngeal Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ipilimumab Nivolumab Radiation in HPV+ Oropharyngeal Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.7%
    Check dated 2025-06-19T19:50:55.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:23:31.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T06:09:32.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version number, changing from v2.15.0 to v2.15.2, and the phrasing regarding the last update has been clarified.
    Difference
    0.1%
    Check dated 2025-04-30T14:25:42.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    The webpage has been updated to reflect a new phase 2 study involving Ipilimumab and Nivolumab for treating HPV-positive oropharyngeal carcinoma, with a new estimated last update date of April 2025.
    Difference
    2%
    Check dated 2025-04-23T13:47:41.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the addition of detailed clinical stages and types of HPV-mediated oropharyngeal carcinoma, as well as the inclusion of a quality-of-life assessment and a new registry identifier. However, extensive information regarding the study's objectives, treatment protocols, and inclusion/exclusion criteria has been removed.
    Difference
    53%
    Check dated 2025-04-16T10:52:10.000Z thumbnail image

Stay in the know with updates to Ipilimumab Nivolumab Radiation in HPV+ Oropharyngeal Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ipilimumab Nivolumab Radiation in HPV+ Oropharyngeal Clinical Trial page.